|Hadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences|
June 19, 2017
|As part of the transaction, HBL, which owns 21% of Cellcure's share capital, will sell its entire holdings to BioTime, Inc., In exchange, BioTime will pay $12.75 million in Biotime shares to HBL
JERUSALEM, June 19, 2017 /PRNewswire/ --
Hadasit Bio-Holdings Ltd. ("HBL") (TASE: HDST) announced that it has completed a share swap transaction with BioTime, Inc., ("BioTime") (TASE: BTX.TA) in their joint portfolio company Cell Cure Neurosciences ("Cell Cure").
The transaction is the first exi... |
|BioTime Expands & Advances Ophthalmology Portfolio|
June 19, 2017
|Expanded Exclusive, Global License to RPE and Photoreceptor Cells
for Use in All Eye Disorders
Data Presented at International Society for Stem Cell Research
Translational Vision Sciences & Technology (TVST) Journal Publishes
ALAMEDA, Calif.--(BUSINESS WIRE)--Jun. 19, 2017--
BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
developing ... |
|OncoCyte Reports Successful Completion of Follow on Breast Cancer Diagnostic Study|
June 15, 2017
|ALAMEDA, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it has successfully completed a follow on study of its breast cancer diagnostic test. The study, known as NICE-BC (Non-Invasive Confirmatory dEtection (of) Breast Cancer, has confirmed the findings of OncoCyte’s previous breast cancer study, which was presented at the San Antonio Breast Cancer Symposium (SABCS) ... |
View Committee Composition
Find the latest financial information
DISCLAIMER: You are about to review presentations, reports, filings and/or other materials regarding BioTime, Inc. (NYSE: MKT and TASE: BTX) that contain time-sensitive information. The information contained therein is only current as of the date thereof. BioTime expressly disclaims any obligation to review, update or correct these materials after the date thereof. BioTime may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.
Certain statements made on this website or in materials accessed in or through this section of our website are "forward-looking statements," which are subject to risks and uncertainties, and BioTime's actual results may differ (possibly materially) from those indicated in such statements.
|Data provided by Nasdaq. Minimum 15 minutes delayed.|